Neximmune announces appointment of dr. leena gandhi to its board of directors

Gaithersburg, md., may 10, 2022 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today announced the appointment of leena gandhi, m.d., ph.d., director for the center of therapeutic innovation at dana-farber cancer institute, to its board of directors as a non-executive director.
NEXI Ratings Summary
NEXI Quant Ranking